secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2026-08-06T11:02:19+00:00
Accession:  0001193125-26-336670
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx Q2 net loss $43.4M; Phase 3 PBH topline data expected late Aug/early Sep 2026
--------------------------------------------------------------------------------

- Net loss of $43.4M ($0.39 per share) vs $41.4M ($0.46 per share) in Q2 2025.
- Cash, equivalents, and short-term investments $250.8M at June 30, 2026; runway into 2028.
- R&D expenses $23.8M (down from $27.2M); SG&A $21.9M (up from $15.6M) on legal and commercial investment.
- Last participant completed final visit in Phase 3 LUCIDITY trial of avexitide in PBH; topline data on track for late Aug/early Sep 2026.
- Expanded Access Program for avexitide initiated; second research collaboration with Gubra A/S announced.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/0001193125-26-336670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312526336670/amlx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer